OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

US biotech OPKO Health (Nasdaq: OPK) and Israeli firm Entera Bio (Nasdaq: ENTX) have entered into a collaboration to develop an oral GLP-1/glucagon dual agonist tablet for obesity, metabolic ...

Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst Y.

Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients ...

In a regulatory filing, Opko Health (OPK) disclosed that its CEO Phillip Frost bought 200K shares of common stock on March 17th in a total ...

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

Microsoft Technical Program Manager Erik Lindeman Joins OnTerra Systems As Director of Product Management & Professional ...